Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Healthcap
BioCentury | Oct 29, 2024
Emerging Company Profile
Kivu: Advancing safer ADCs against established targets
Company launches with $92 million to develop antibody-drug conjugates spun out of Synaffix
BioCentury | May 30, 2024
Finance
Venture Report: Canadian VC Amplitude closes new fund; CinRx’s series C
Plus: Adcendo’s series A is again Denmark’s largest; VCs and foundations back Lucy
BioCentury | Apr 26, 2024
Finance
Venture report: Arch, Foresite $1B AI play Xaira starting with Baker lab’s de novo biologics
Plus rounds for Rubedo, Flindr, Endeavor, SynOx and more
BioCentury | Mar 19, 2024
Deals
AZ deepens radiopharma commitment via $2B Fusion takeout
Deal brings more momentum for α-emitters, with Fusion’s lead program contrasting Novartis’ β-emitting Pluvicto
BioCentury | Nov 29, 2023
Deals
Nov. 28 Quick Takes: BMS, Avidity adding targets to discovery deal
Plus: Acelyrin says CRO Fortrea erred in psoriatic arthritis study, Aro raises $41.5M for tissue-targeted siRNA pipeline
BioCentury | Oct 25, 2023
Deals
Oct. 24 Quick Takes: BMS buying back Asia rights to mavacamten from LianBio
Plus: Rampart raises $85M series A for DNA-based therapies and updates from Servier, Novartis, Cargo and more
BioCentury | Apr 4, 2023
Deals
April 4 Quick Takes: Scorpion, Pierre Fabre enter deal for pair of EGFRs
Plus: EUA for InflaRx’s antibody for COVID-19 and updates from Adcendo, Mercy, Mosaic, Freeline and Gossamer
BioCentury | Feb 22, 2023
Regulation
Feb. 21 Quick Takes: Crossovers back Hemab in $135M series B
Plus: FDA reviewing Onpattro for larger ATTR indication; EU gets first hemophilia B gene therapy; and updates from Merck, Pfizer and more
BioCentury | Sep 21, 2022
Deals
Carisma to reach NASDAQ via Sesen merger
After evaluating options, Sesen chooses Carisma option among dozens of bids, creating third incarnation of public company
BioCentury | Sep 14, 2022
Emerging Company Profile
Pretzel: modulating the mitochondrial genome
Arch-incubated newco launched Monday with $72.5M and three platforms to tackle mitochondrial diseases
Items per page:
1 - 10 of 257